Hemophilia A
Conditions
Brief summary
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating physician independently from the decision to include patients in the study. No study medication is provided. The data related to efanesoctocog alfa effectiveness, safety and usage will be collected prospectively during routine visits (expected annual/semi-annual visits) for up to 5 years following enrollment /treatment initiation.
Interventions
DRUGEfanesoctocog Alfa BIVV001
Given per investigator's discretion
Sponsors
Sanofi
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Have a diagnosis of hemophilia A * Patients starting efanesoctocog alfa treatment as per standard of care no more than one month prior to the enrollment date, for either on demand or prophylaxis. Patients starting efanesoctocog alfa treatment for a surgery event may also be enrolled only if the treatment is prescribed at enrollment. * Physician's decision to treat the patient with efanesoctocog alfa is made prior to and independently of participation in the study. * Signed and dated informed consent provided by the patient, or by the patient's legally acceptable representative for patients under the legal age before any study-related activities are undertaken. Assent should be obtained for pediatric patients according to local regulations.
Exclusion criteria
Diagnosed with other known bleeding disorder * Participation in an investigational medicinal product trial at enrollment visit, or intake of an Investigational Medicinal Product within 3 months prior to inclusion in this study * Current diagnosis of a FVIII inhibitor, defined as inhibitor titer ≥0.60 BU/mL The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in Annualized joint bleeding rate (AjBR) for treated bleeds | Up to 5 years | Data will be reported for the effectiveness of efanesoctocog alfa prophylaxis on clinical joint status over 5-years for prophylactic cohort |
| Change from baseline in Annualized joint bleeding rate (AjBR) for all (treated and untreated) bleeds | Up to 5 years | Data will be reported for the effectiveness of efanesoctocog alfa prophylaxis on clinical joint status over 5-years for prophylactic cohort |
| Number of Target joint development, resolution and/or recurrence | Up to 5 years | Data will be reported for the effectiveness of efanesoctocog alfa prophylaxis on clinical joint status over 5-years for prophylactic coho |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ABR by type all (treated and untreated) bleeds | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| ABR by location for treated bleeds | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| ABR by location for all (treated and untreated) bleeds | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| ABR for all bleeding episodes (including untreated bleeding episodes) | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| Percentage of patients with zero joint bleeds | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| Annualized factor consumption per participant (IU/kg) assessed by prescription during the follow-up period. | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| Annualized injection frequency per participant (assessed by prescription) during the follow- up period | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| Treatment adherence (%) as judged by the physician during the follow-up period | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
| Number of injections of efanesoctocog alfa to treat a bleeding episode. | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (Sub Cohorts A1 and A2) |
| Total dose of efanesoctocog alfa to treat a bleeding episode. | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (Sub Cohorts A1 and A2) |
| Number of injections of efanesoctocog alfa to treat a bleeding episode | At 1, 2, 3, 4, 5 years | Data will be reported for On-demand cohort |
| Total dose of efanesoctocog alfa to treat a bleeding episode | At 1, 2, 3, 4, 5 years | Data will be reported for On-demand cohort |
| Percentage of bleeding episodes treated with a single injection of efanesoctocog alfa. | At 1, 2, 3, 4, 5 years | Data will be reported for On-demand cohort |
| Occurrence of a change in treatment regimen (on-demand to prophylactic or prophylactic to on-demand) at baseline and follow-up. | At 1, 2, 3, 4, 5 years | Data will be reported for On-demand cohort |
| Change from baseline in Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) total/domain scores | At 1, 2, 3, 4 and 5 years | HEAD-US total/domain scores will be reported for joint imaging sub cohort |
| Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) pain intensity 3a questionnaire (adults) | At 3 months, 6 months, 1, 2, 3, 4 and 5 years | Effectiveness of efanesoctocog alfa assessed per participants' PROs in all participants |
| Change from baseline in synovial hypertrophy by change in mm thickness AND/OR HEAD-US synovitis domain, AND/OR by JADE MSKUS synovial hypertrophy +/- power doppler signal | At 6 months, 1, 2, 3, 4 and 5 years | Data will be reported from the consenting participants from the joint imaging sub-cohort |
| Occurrence of adverse events (AEs) and serious adverse events (SAEs) | Over 5 year period | The safety and tolerability of efanesoctocog alfa over 5 years evaluated in all participants |
| Development of inhibitors (neutralizing antibodies directed against factor FVIII as determined via the Nijmegen modified Bethesda assay. | Over 5 year period | The safety and tolerability of efanesoctocog alfa over 5 years assessed in all participants |
| Change from baseline in Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) 3.0 (boys ≤18 years old) questionnaire (including Parent Proxy) | At 1, 2, 3, 4 and 5 years | Effectiveness of efanesoctocog alfa assessed per participants' PROs in all participants |
| Change from baseline in the occurrence of inpatient and outpatient visits, and length of hospital stay related to hemophilia A | At 1, 2, 3, 4 and 5 years | Healthcare resource use (HCRU) in efanesoctocog alfa related to hemophilia A over a 5-year period |
| Hemostatic response/physician reported during peri-operative period for surgery (major, minor) with efanesoctocog alfa. | Over a 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Number of injections required to maintain hemostasis during perioperative period for surgery (major, minor) | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Dose per injection required to maintain hemostasis during perioperative period for surgery (major, minor) | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Total efanesoctocog alfa consumption (IU) during perioperative period for surgery (major, minor) | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Number of blood component transfusions used during perioperative period for surgery | Over 5 year Period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Type of blood component transfusions used during perioperative period for surgery | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Estimated blood loss (ml) (intraoperative and post-operative period) for major surgery | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Number of transfusions required for surgery (intraoperative and post-operative period) | Over 5 year period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period |
| Duration of hospitalization (major, minor) | Over 5 years period | Data reported to describe the usage and effectiveness of efanesoctocog alfa during the perioperative period. |
| Change from baseline in Hemophilia Early Arthropathy Detection with Joint Tissue Activity and Damage exam (JADE) musculoskeletal ultrasound (MSKUS) (JADE MSKUS) | At 1, 2, 3, 4 and 5 years | Data will be reported for consenting participants from the joint imaging sub-cohort |
| Change from baseline in the Hemophilia Joint Health Score (HJHS v2.1) total/domains scores | At 1, 2, 3, 4, 5 years | HJHS total/domain scores will be reported for prophylactic cohorts (A1 ad A2) |
| Annual Bleeding Rate (ABR) by type for treated bleeds | At 1, 2, 3, 4, 5 years | Data will be reported for prophylactic cohorts (A1 and A2) |
Countries
United States
Outcome results
None listed